Introduction
============

Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the t(9; 22) and the related oncogene, *BCR/ABL* ([@b116-btt-1-433]; [@b141-btt-1-433]; [@b37-btt-1-433]). The respective fusion gene product, BCR/ABL, is a cytoplasmic 210 kDa protein that is considered essential for growth and survival of leukemic cells ([@b36-btt-1-433]; [@b101-btt-1-433]; [@b58-btt-1-433]; [@b175-btt-1-433]; [@b12-btt-1-433]; [@b135-btt-1-433]). BCR/ABL displays constitutive tyrosine kinase (TK) activity and triggers a number of downstream signalling molecules including phosphoinositide 3-kinase (PI3K), mitogen-activated protein (MAP) kinase, nuclear factor-κB (NFκB), RAS, and signal transducer of activation and transcription 5 (STAT5) ([@b123-btt-1-433]; [@b130-btt-1-433]; [@b152-btt-1-433]; [@b150-btt-1-433]; [@b143-btt-1-433]; [@b108-btt-1-433]; [@b162-btt-1-433]). These signalling molecules and pathways supposedly act together to promote malignant transformation, to enhance genetic instability, and to suppress apoptosis in leukemic cells ([@b75-btt-1-433]; [@b108-btt-1-433]; [@b162-btt-1-433]).

The (natural) clinical course in CML can be divided into a chronic (early) phase (CP), in which cellular differentiation and maturation are largely preserved, an accelerated phase (AP) of the disease, and a terminal (=blast) phase of CML (CML-BP), which resembles acute leukemia ([@b31-btt-1-433]; [@b55-btt-1-433]; [@b34-btt-1-433]). In addition, based on the detection of BCR/ABL in apparently healthy subjects, a prephase of CML (with normal leukocyte counts), in which clonal BCR/ABL+ stem cells expand and generate subclones ([@b12-btt-1-433]; [@b15-btt-1-433]), has been postulated ([Figure 1](#f1-btt-1-433){ref-type="fig"}). What hits drive BCR/ABL-positive cells (subclones) from a prephase into overt CML, remains at present unknown. It also remains uncertain whether a 'pre-BCR/ABL-phase' of CML exists, in which monoclonal but preleukemic stem cell clones develop and expand to provide a suitable cellular background for the establishment of a BCR/ABL+ clone ([Figure 1](#f1-btt-1-433){ref-type="fig"}). This hypothesis has been based on rare cases of BCR/ABL-negative but apparently monoclonal populations of leukemic cells (subclones) that may develop in CML patients during treatment with imatinib. All in all, BCR/ABL is considered a most critical factor, but may per se not be sufficient for disease-initiation. Also, whereas in CP, BCR/ABL is considered to play a predominant role for leukemia cell survival, additional pro-oncogenic molecules and pathways may become (more) important and contribute to malignant growth and thus disease-progression in advanced CML (AP, BP) ([@b148-btt-1-433]; [@b143-btt-1-433]; [@b24-btt-1-433]; [@b107-btt-1-433]) ([Figure 1](#f1-btt-1-433){ref-type="fig"}).

The leukemic clone in CML is organized hierarchically, with more mature cells that have a limited capacity to divide and to survive, and cells with unlimited capacity to divide and to self-renew, so-called leukemic stem cells ([@b48-btt-1-433], [@b47-btt-1-433]; [@b72-btt-1-433], [@b73-btt-1-433]; [@b50-btt-1-433]; [@b51-btt-1-433]). Taking this concept into consideration, it seems clear that the clinically relevant portion of MRD and any resulting relapse derives from CML stem cells, and that therapy is curative only when eradicating these cells. During disease evolution and probably even before overt disease is diagnosed (prephase of CML), CML stem cells may acquire multiple (transforming) hits, resulting in subclone-formation ([@b73-btt-1-433]; [@b83-btt-1-433]). Therefore, the CML clone supposedly is composed of several different subclones at diagnosis in most (if not all) patients, a hypothesis that explains the 'occurrence' of drug-resistant BCR/ABL-mutants during therapy through subclone-selection ([@b137-btt-1-433]; [@b83-btt-1-433]). An unresolved question is why wild type (wt) BCR/ABL-bearing cells have a growth advantage over subclones exhibiting BCR/ABL-mutants. In fact, in most patients, the mutant subclone is only detectable after initiation of BCR/ABL-targeting therapy. A related question is how the disease can suppress growth of normal hematopoietic stem cells. Here, one hypothesis is, that stem cell-derived negative growth-regulators (chalones) such as lipocalin, suppress growth of normal (stem) cells through a specific receptor, whereas CML stem cells are resistant, as they display only low amounts or lack lipocalin-binding sites ([@b40-btt-1-433]; [@b98-btt-1-433]). Whether mutant BCR/ABL-bearing subclones are also suppressed by leukemic cells displaying wt BCR/ABL through chalone-dependent inhibition or other mechanisms, remains unknown.

The BCR/ABL kinase inhibitor imatinib has successfully been introduced in the treatment of CML. Thus, imatinib induces major cytogenetic responses in a majority of all patients with CP CML ([@b43-btt-1-433]; [@b87-btt-1-433]; [@b8-btt-1-433]; [@b117-btt-1-433]). Responses are also seen in (some) patients with AP or BP ([@b44-btt-1-433]; [@b156-btt-1-433]; [@b87-btt-1-433]; [@b144-btt-1-433]). However, despite overwhelming initial data and high expectations, little is known about long-term effects of imatinib ([@b42-btt-1-433]). An apparent result from follow up studies is that imatinib is unable to eradicate all neoplastic stem cells (subclones) in CML. Rather, many patients develop overt resistance against imatinib during therapy, which is often associated with the outgrowth of subclones bearing mutations in *BCR/ABL* ([@b16-btt-1-433], [@b17-btt-1-433]; [@b86-btt-1-433]; [@b69-btt-1-433]). For such patients, treatment options are usually limited. In fact, many of them are in AP or BP, and only a subgroup of them are eligible for stem cell transplantation (SCT).

Therefore, a number of attempts have been made to identify new drugs that act antileukemic in imatinib-resistant CML ([@b147-btt-1-433]; [@b168-btt-1-433], [@b172-btt-1-433]; [@b120-btt-1-433]; [@b104-btt-1-433]). Such drugs are directed against BCR/ABL and its mutants, but may also be directed against other (BCR/ABL-independent) molecules that play a role in malignant transformation ([@b104-btt-1-433]; [@b172-btt-1-433]). Thus, molecular resistance against imatinib may not only be caused by changes in *BCR/ABL*, but also by other pro-oncogenic molecules ([@b86-btt-1-433]; [@b69-btt-1-433]). Therefore, less specific targeted drugs and combinations of targeted drugs have been proposed, and are currently applied in clinical trials to overcome resistance. Some of the emerging TK inhibitors act on BCR/ABL as well as on other key signalling targets, such as Lyn or/and other Src kinases ([@b147-btt-1-433]; [@b104-btt-1-433]; [@b92-btt-1-433]; [@b173-btt-1-433]).

Apart from molecular resistance against imatinib, other mechanisms that cause resistance in CML, have also been described. First, immature leukemic cells (stem cells) may exhibit intrinsic (BCR/ABL-independent) resistance ([@b9-btt-1-433]; [@b84-btt-1-433]). Second, a number of cellular molecules involved in the regulation of drug-uptake, drug-metabolism or drug-efflux, may influence the bio-availability of imatinib ([@b68-btt-1-433]; [@b77-btt-1-433]; [@b160-btt-1-433]; [@b167-btt-1-433]; [@b21-btt-1-433]). Lastly, more and more data suggest that imatinib is not capable of entering all organ-compartments in vivo. Likewise, imatinib is unable to cross the blood-brain barrier in amounts sufficient to reach a pharmacologic drug concentration in the central nervous system (CNS) ([@b154-btt-1-433]; [@b145-btt-1-433]; [@b38-btt-1-433]; [@b178-btt-1-433]). Correspondingly, CNS relapses are increasingly described in CML patients treated with imatinib ([@b1-btt-1-433]; [@b96-btt-1-433]; [@b14-btt-1-433]; [@b134-btt-1-433]; [@b142-btt-1-433]; [@b105-btt-1-433]; [@b122-btt-1-433]; [@b91-btt-1-433]; [@b5-btt-1-433]).

In the following sections, various types of resistance against imatinib are discussed together with possibilities to prevent or to overcome resistance with currently available drugs, combination strategies employing drugs and SCT, or future therapeutic approaches such as siRNA or immunotherapies.

Leukemic stem cells exhibit 'intrinsic resistance'
==================================================

Most patients in CML CP enter a complete cytogenetic response (CCR) during treatment with imatinib ([@b43-btt-1-433]; [@b87-btt-1-433]; [@b8-btt-1-433]; [@b117-btt-1-433]). In many of these patients, BCR/ABL-transcripts decrease to low or even undetectable levels over time ([@b8-btt-1-433]; [@b76-btt-1-433]; [@b42-btt-1-433]). However, discontinuation of imatinib is usually followed by a cytogenetic and hematologic relapse ([@b20-btt-1-433]; [@b140-btt-1-433]). Based on this observation and other studies, it has been hypothesized that MRD in imatinib-treated patients contains leukemic stem cells (clinically relevant subclones), and that these residual stem cells exhibit imatinib-resistance ([@b62-btt-1-433]; Bhatia et al 2003; [@b110-btt-1-433]; [@b59-btt-1-433]; [@b39-btt-1-433]). A remarkable aspect is that the relapsing subclones that reappear after discontinuation of imatinib usually display wt BCR/ABL. Therefore, apart from well known molecular mechanisms (BCR/ABL mutations) leading to resistance, stem cell resistance against imatinib in CML is also considered to result from stem cell-related (intrinsic) mechanisms. The exact molecular basis of intrinsic stem cell resistance against imatinib is not well understood. The different hypotheses that have been raised are summarized in [Table 1](#t1-btt-1-433){ref-type="table"}. Apart from stem cell quiescence and overexpression of BCR/ABL, these cells may also utilize BCR/ABL-independent survival mechanisms ([@b30-btt-1-433]; [@b29-btt-1-433]; [@b9-btt-1-433]; [@b84-btt-1-433]). In addition, it has been hypothesized that imatinib-resistance in CML stem cells may be associated with reduced drug-uptake and increased drug-efflux. In particular, compared to more mature clonal cells, CML stem cells (CD34+/CD38−/Lin−) apparently display decreased levels of organic cation transporter-1 (OCT-1), a surface transporter involved in the uptake of imatinib, and increased levels of drug-efflux-related surface molecules including the multi-drug resistance protein-1 (MDR-1), known to mediate the efflux of imatinib ([@b84-btt-1-433]). Efflux mechanisms may also contribute to resistance against other drugs including new BCR/ABL TK inhibitors, such as nilotinib (AMN107) ([@b21-btt-1-433]). More recently, it has been described, that dasatinib may act better on immature CML (stem) cells compared to imatinib, but still may not be capable of killing all leukemic stem cells (subclones) ([@b29-btt-1-433]). An interesting approach to measure the response to imatinib on a qualitative basis and to possibly predict the response (and relapse) in progenitor compartments, are recently proposed mathematical models ([@b110-btt-1-433]; [@b138-btt-1-433]). It may be an interesting idea to employ such models in forthcoming clinical trials studying new TK inhibitors or combination therapies.

As outlined above, stem cell resistance in CML is an emerging issue and major focus in clinical and preclinical research, and although it is difficult to purify CML stem cells for in vitro investigations, the availability of sensitive MRD parameters offers a valuable basis for the design of clinical trials examining the effects of novel drugs and drug-combinations on residual leukemic stem cells. For the near future, one of the most important questions will be whether any of the new TK inhibitors, like dasatinib, nilotinib, INNO-406, or others, can induce long-lasting CCR and consecutive cure through eradication of all relevant CML stem cell subclones in CP. Respective clinical trials employing dasatinib or nilotinib as frontline therapy in CML CP are in progress. These trials should reveal the exact curative potential of these drugs and thus will answer the question as to whether they can overcome 'intrinsic stem cell resistance'. It should be mentioned here that not all CML stem cell subclones may be of clinical relevance (causing relapse), and that some of these patients may stay in complete hematologic remission even if a BCR/ABL+(sub)clone is detectable ([@b64-btt-1-433]; [@b90-btt-1-433]; [@b59-btt-1-433]).

The next important question would be whether combinations of targeted drugs may (better) overcome stem cell resistance against imatinib. First, some of these combinations may facilitate the uptake of imatinib or other BCR/ABL TK inhibitors in CML stem cells, or may prevent enhanced drug efflux from these cells ([@b102-btt-1-433]; [@b160-btt-1-433]; [@b77-btt-1-433]). Likewise, a number of MDR-1 blockers (cyclosporin-A, verapamil, others) are available, and it may be an interesting approach to combine such inhibitors with imatinib or other BCR/ABL TK inhibitors to enhance intracellular drug levels in CML stem cells. More recently, it has been described that combinations of TK inhibitors with each other may also enhance intracellular levels of individual drugs and thereby may lead to cooperative (synergistic) antileukemic effects ([@b176-btt-1-433]). Indeed, most of the BCR/ABL TK inhibitors exert synergistic antileukemic effects on CML cells ([@b172-btt-1-433]).

Another important aspect is that conventional antileukemic drugs such as interferon-alpha, may have a more pronounced effect on CML progenitor cells compared with imatinib ([@b4-btt-1-433]; [@b163-btt-1-433]). Therefore, several trials employ combinations between interferon-alpha and BCR/ABL TK inhibitors. Another important aspect is that many of the novel inhibitors are less specific drugs that do not only recognize BCR/ABL, but also (many) other key kinase-targets ([@b147-btt-1-433]; [@b104-btt-1-433]; [@b92-btt-1-433]; [@b172-btt-1-433]). The differential target profiles of TK inhibitors may also explain why several of them, when combined, produce synergistic antileukemic effects ([@b170-btt-1-433]). In this regard it may be of great importance to learn which kinase-targets and related pathways play a predominant role in the biology and growth of CML stem cells. An important consideration in this regard is that the biology, function, and target expression profiles of CML stem cells may be similar but not identical to that of normal stem cells, and that the profile may change during disease evolution, ie, progression to AP or BP ([@b180-btt-1-433]; [@b132-btt-1-433]; [@b164-btt-1-433]; [@b41-btt-1-433]).

Lastly, it has to be emphasized that the only established stem cell eradicating (=curative) therapy in CML remains SCT, and that SCT may also work in a group of patients with advanced CML ([@b60-btt-1-433]; [@b149-btt-1-433]; [@b63-btt-1-433]; [@b45-btt-1-433]; [@b39-btt-1-433]). It also has been described that pre-transplant therapy with imatinib may be a reasonable approach in advanced CML ([@b57-btt-1-433]; [@b173-btt-1-433]). Moreover, SCT should remain an important option and major decision-point in treatment algorithms in imatinib-resistant CML ([@b78-btt-1-433]). Depending on the clinical situation and other factors, such therapy (SCT) may be combined with BCR/ABL TK inhibitors ([@b109-btt-1-433]). Likewise, patients with imatinib-resistant CML in AP or BP who are young and have a suitable donor, may benefit from targeted therapy with a second generation BCR/ABL TK inhibitor inducing remission or at least disease-reduction (debulking), followed by allogeneic SCT ([@b80-btt-1-433]; [@b109-btt-1-433]). As to whether such patients should also be treated with the same BCR/ABL TK inhibitors after SCT (maintenance, prophylaxis) remains at present unknown. At least for patients with detectable BCR/ABL after SCT, maintenance therapy should be considered. Patients who fail SCT or relapse after SCT may also benefit from new TK inhibitors. Whether such patients may even have a better outcome when receiving combination therapy (drug-combinations or donor lymphocytes plus a TK inhibitor) remains to be defined.

Pharmacologic aspects and pharmacologic resistance
==================================================

Orally administered imatinib is rapidly (within 1--2 hours) and completely absorbed, with a bioavailability of \>95%, and a peak plasma concentration reached after 2--4 hours ([@b28-btt-1-433]; [@b127-btt-1-433]). The pharmacologic half-life of the drug is approximately 18 hours ([@b28-btt-1-433]; [@b94-btt-1-433]; [@b124-btt-1-433], [@b127-btt-1-433]). At a daily dose of 400 mg, imatinib plasma concentrations peak to about 2--3 μg/mL, with a trough level of approximately 1 μg/mL ([@b94-btt-1-433]; [@b124-btt-1-433], [@b127-btt-1-433]), which exceeds imatinib-doses required for complete inhibition of wt BCR/ABL TK activity (0.5 μg/mL = 1 μM). Imatinib is \>95% bound to human plasma proteins, mainly albumin and alpha1-acid glycoprotein ([@b28-btt-1-433]; [@b127-btt-1-433]). The drug is eliminated predominantly via the bile in form of metabolites ([@b28-btt-1-433]; [@b65-btt-1-433]; [@b127-btt-1-433]). One of these metabolites, CGP74588, exhibits pharmacological activity comparable to the parent-drug ([@b28-btt-1-433]). Imatinib is metabolized via cytochrome (CYP) P450 isoenzymes, primarily CYP3A4, but also by other CYP 450 species (CYP3A5, CYP2D6). Therefore, imatinib can competitively inhibit the metabolism of drugs that are substrates of CYP P450 isoenzymes ([@b28-btt-1-433]; [@b117-btt-1-433]). Vice versa, drugs that are metabolized via or are inducers of these CYP enzymes may influence the bioavailability of imatinib, and thus lead to changes (eg, decrease) in imatinib plasma concentrations ([@b28-btt-1-433]; [@b13-btt-1-433]; [@b46-btt-1-433]; [@b52-btt-1-433]). Also, hepatic and renal dysfunction may result in slight changes in imatinib concentrations in biological fluids and tissues ([@b127-btt-1-433]; [@b121-btt-1-433]; [@b49-btt-1-433]). However, these changes usually are mild and do not require dose-adjustments. Age, race, sex, and bodyweight have no documented influence on the pharmacokinetics or pharmacodynamics of imatinib ([@b127-btt-1-433]).

From experience in clinical trials, patients with CML are judged to be imatinib-resistant when response is lost or is not seen with a daily dose of \>400 mg imatinib ([@b89-btt-1-433]; [@b7-btt-1-433]). Studies on pharmacokinetics and pharmacodynamics of imatinib in CML suggest that a minimum dose of imatinib of 350--400 mg daily is required to reach a constant effective drug concentration in plasma, that would block wt BCR/ABL ([@b125-btt-1-433]). However, no detailed studies on tissue-concentrations of imatinib in various organs have been presented so far, and some of the tissues and organ-compartments (brain) may not be reached sufficiently by imatinib. In addition, a number of genetic and other factors may influence the bioavailability of the drug ([@b127-btt-1-433]; [@b121-btt-1-433]; [@b49-btt-1-433]). Moreover, the expression of drug transporters and drug-efflux pumps, that are expressed in the apical membrane of the small intestine and the bile canalicular membrane, have been implicated in pharmacologic resistance ([@b22-btt-1-433]; [@b23-btt-1-433]). All in all, a number of factors may influence the plasma- and tissue levels of imatinib, and under certain circumstances, may contribute to pharmacologic resistance.

More recent data suggest that pharmacologic resistance may indeed be of clinical relevance. In fact, it has been described that the trough plasma level of imatinib is associated with the rate of CCR and of major molecular responses (MMR) in patients with CML ([@b128-btt-1-433]). In particular, significantly higher trough levels were found in patients with CCR and MMR (often \>1 μg/ml) compared to those without CCR or MMR (often \<1 μg/ml) ([@b128-btt-1-433]). An unresolved question is whether the different trough levels in the two groups of patients resulted from a primary defect(s) in bioavailability (true pharmacologic resistance) or from massive drug-uptake by residual CML cells in less well responding patients. Whatever the reason is, the observation of different trough levels may be of clinical significance, and it seems appropriate to recommend that plasma trough levels are measured in patients with otherwise unexplained suboptimal response (or no response) to imatinib.

A number of different strategies have been proposed to overcome pharmacologic resistance against imatinib. Suspicion for pharmacologic resistance must be raised when cytogenetic (and molecular) response is lost or not achieved, no BCR/ABL mutations and no signs of clonal evolution are found, and trough imatinib levels are low. It is then important to ask for possible drug-interactions, patient's complience, and concomitant disorders. After having excluded such causes, dose adjustments (increase) should be considered and may lead to a better response ([@b89-btt-1-433]). Another potential strategy, that may become subject of future studies, would be to try to increase the imatinib uptake in the intestinal wall (and in other critical target cell populations), and thus bioavailability of the drug, or by imatinib with modulators of transport-proteins ([@b18-btt-1-433]).

'Anatomic resistance' against imatinib
======================================

A special problem with imatinib is its marginal accumulation in the central nervous system (CNS) which is caused by low uptake via the blood-brain barrier ([@b154-btt-1-433]; [@b145-btt-1-433]; [@b38-btt-1-433]; [@b178-btt-1-433]). The biochemical basis of poor uptake is not well understood. One hypothesis is that the abundant expression of MDR-1 (P-glycoprotein) in cells forming the blood-brain barrier is associated with constant drug-efflux ([@b38-btt-1-433]; [@b19-btt-1-433]; [@b18-btt-1-433]). Clinically, the poor uptake into the CNS is reflected by CNS relapses that occur in imatinib-treated patients ([@b1-btt-1-433]; [@b96-btt-1-433]; [@b14-btt-1-433]; [@b134-btt-1-433]; [@b142-btt-1-433]; [@b105-btt-1-433]; [@b122-btt-1-433]; [@b91-btt-1-433]). This is a well known problem in lymphoid leukemias and in the lymphoid blast phase of CML. However, more recently, myeloid CNS relapses have also been described ([@b142-btt-1-433]; [@b5-btt-1-433]). Some of these CNS relapses occur even in patients with CCR ([@b14-btt-1-433]; [@b5-btt-1-433]).

A number of strategies have been proposed to treat and to prevent CNS relapses in CML. Once diagnosed, local therapy of the CNS relapse with intrathecal cytostatic drugs (cytarabine and others) and/or radiation seems an appropriate therapeutic maneuver ([@b1-btt-1-433]; [@b96-btt-1-433]; [@b14-btt-1-433]; [@b134-btt-1-433]; [@b142-btt-1-433]; [@b105-btt-1-433]; [@b122-btt-1-433]; [@b91-btt-1-433]; [@b5-btt-1-433]). In those with a concomitant systemic relapse, the additional replacement of imatinib by a second generation BCR/ABL inhibitor must be considered ([@b2-btt-1-433]; [@b5-btt-1-433]). Interestingly, for some of these emerging drugs (dasatinib, INNO-406), it has been described that they can cross the blood-brain barrier quite effectively in animal models ([@b177-btt-1-433]; [@b179-btt-1-433]), and the same may hold true for patients with CML in CNS relapse ([@b2-btt-1-433]; [@b5-btt-1-433]). Therefore, it seems logic to consider the use of such new TK inhibitors as prophylaxis of CNS relapses as well. In case that the frequency of reported CNS relapses will further increase, such prophylactic therapy must be regarded as a mandatory approach. An alternative approach might be to increase the uptake of imatinib by applying modulators of drug transporters (eg, MDR-1).

BCR/ABL mutations
=================

The predominant molecular defect that causes resistance against imatinib are point mutations in the *BCR/ABL* oncogene ([@b61-btt-1-433]; [@b166-btt-1-433]; [@b10-btt-1-433]; [@b16-btt-1-433], [@b17-btt-1-433]; [@b146-btt-1-433]; [@b71-btt-1-433]). The respective BCR/ABL mutants retain their kinase activity and their oncogenic potential, but usually display impaired or absent drug-binding capacity ([@b139-btt-1-433]; [@b6-btt-1-433]; [@b35-btt-1-433]; [@b172-btt-1-433]). Other mutants may be less oncogenic and may not play an important role in disease evolution ([@b64-btt-1-433]; [@b90-btt-1-433]). Most of the relevant mutations cluster within or in next vicinity to the imatinib-binding site, or are located in *BCR/ABL* domains critical to the topography and tertiary structure of the imatinib/ATP-binding site, with consecutive steric hindrance of drug-binding ([@b16-btt-1-433], [@b17-btt-1-433]; [@b146-btt-1-433]; [@b71-btt-1-433]; [@b139-btt-1-433]; [@b6-btt-1-433]; [@b35-btt-1-433]; [@b120-btt-1-433], [@b172-btt-1-433]). Examples of *BCR/ABL* residues that (when derived from mutated genes) directly inhibit imatinib-binding, are Thr315 and Phe317 ([@b35-btt-1-433]; [@b172-btt-1-433]). Other *BCR/ABL* mutations destabilize the inactive conformation of the nucleotide-binding loop (P-loop) or the DFG motif that binds to imatinib, thereby reducing imatinib-binding affinity ([@b139-btt-1-433]; [@b35-btt-1-433]; [@b172-btt-1-433]). Residues affecting imatinib-binding through destabilization of the inactive conformation include Glu255, Tyr253, and Gly250 in the P-loop of *ABL* ([@b35-btt-1-433]; [@b172-btt-1-433]).

More than 50 different mutations in *BCR/ABL* have been described ([@b166-btt-1-433]; [@b146-btt-1-433]; [@b71-btt-1-433]; [@b35-btt-1-433]; [@b120-btt-1-433]; [@b172-btt-1-433]). These mutations cluster in four major regions of the oncogene, namley the phosphate-binding (P-loop) domain (examples: M224V, L248V, G250E/R, Q252R/H, Y253F/H, E255K/V), the imatinib-binding domain (F311L/I, T315I, F317L), the catalytic domain (M351T, E355G/D), and the activation loop domain (V379I, F382L, L387M, H396R/P) ([@b146-btt-1-433]; [@b17-btt-1-433]; [@b71-btt-1-433]). [Table 2](#t2-btt-1-433){ref-type="table"} shows *BCR/ABL* mutations frequently detected in patients with imatinib-resistant CML.

In most CML patients, *BCR/ABL* mutations may already be present in (stem cell) subclones before imatinib therapy is initiated ([@b137-btt-1-433], [@b136-btt-1-433]; [@b93-btt-1-433]; [@b83-btt-1-433]). However, in some patients, the *BCR/ABL* mutation may not simply be revealed through selection by drug-therapy, but may represent a newly occurring defect. An unresolved question in this regard is whether treatment with imatinib or other (targeted) drugs can modulate (increase) the *BCR/ABL* mutation rate (mutagenic potential of drug). The more likely scenario is that the rapid and sustained elimination of all (many) subclones by TK inhibitors is important and should counteract the development of new *BCR/ABL* mutations, because the size of the target cell population (CML stem cells) in which such mutations can develop, is constantly shrinking over time in responding patients.

Another unresolved question is how the wt BCR/ABL subclone is capable of suppressing (all) BCR/ABL mutants. This phenomenon may be explained by chalone-dependent inhibition or may be related to the different oncogenic potencies of the mutants. Clinically, this phenomenon is of diagnostic importance, as *BCR/ABL* mutations may not be detectable at diagnosis but only after drug-induced selection of stem cell subclones.

As mentioned above, the various BCR/ABL mutants display different oncogenic (transforming) potential ([@b64-btt-1-433]; [@b151-btt-1-433]; [@b171-btt-1-433]). Taking their in vitro activity into consideration, the following rank order of (oncogenic) potency is found: Y253F = E255K \> wt BCR-ABL \> T315I \> H396P \> M351T \> others. Thus, certain P loop mutations (Y253F, E255K) and the T315I mutation display a high oncogenic potential, which is consistent with the clinical observation of a poor outcome concerning overall and progression-free survival ([@b17-btt-1-433]; [@b153-btt-1-433]; [@b115-btt-1-433]). However, not all P-loop mutations may be associated with a poor prognosis in CML ([@b82-btt-1-433]). In particular, several of the *BCR/ABL* mutations are far less oncogenic, and some of them may not even exhibit a proliferative advantage over normal (stem) cells, and thus may not even cause overt CML ([@b90-btt-1-433]). These mutations should not count in the evaluation of drug resistance and the consecutive treatment plan in the same way as clinically relevant (oncogenic) mutations.

A number of different strategies have been proposed to treat patients with imatinib resistant CML, in whom *BCR/ABL* mutations are detected. Treatment in these patients depends on several different factors, including the type (oncogenic potential) of the mutation, phase of disease, presence of other pro-oncogenic disease-features (clonal evolution), age, co-morbidity, overall status of the patient, and availability of a SCT donor in those who are eligible for high-dose therapy. With regard to *BCR/ABL* mutations, four categories are proposed and related to specific treatment recommendations: a) mutations that do not cause clinically overt resistance (recommendation: wait and watch if possible), b) mutants that have low oncogenic potential and may disappear (at least kept under control) upon dose-escalation (recommendation: increase imatinib from 400 to 600 or 800 mg/day), c) non-T315I-mutants that are not expected to disappear on imatinib dose-escalation (recommendation: switch from imatinib to a second generation BCR/ABL inhibitor: nilotinib or dasatinib), and d) the T315I mutant as well as a few other mutants that are also resistant against dasatinib and nilotinib (recommendation: high-dose chemotherapy or experimental drugs and proceed to SCT if possible). The majority of all imatinib-resistant patients are in group b and c. Therefore, recent efforts have focused on the development of new, more effective BCR/ABL TK inhibitors that can overcome resistance. Among these are nilotinib (AMN107), dasatinib (BMS354825), INNO-406, and several others ([Table 3](#t3-btt-1-433){ref-type="table"}). These drugs act on various imatinib-resistant BCR/ABL mutants and can produce complete hematologic and cytogenetic responses in patients with imatinib-resistant disease ([@b155-btt-1-433]; [@b86-btt-1-433]; [@b169-btt-1-433]; [@b131-btt-1-433]; [@b70-btt-1-433]; [@b33-btt-1-433]; [@b66-btt-1-433]). Encouraging results have particularly been obtained in CP, but hematologic and sometimes cytogenetic or molecular responses may also be seen in AP or BP. However, as stated above, not all BCR/ABL mutants are responsive to these inhibitors, and the relative potencies vary among drugs. Unfortunately, patients with the T315I mutant of BCR/ABL are clinically resistant against nilotinib and dasatinib, and also against most other available TK inhibitors ([@b155-btt-1-433]; [@b88-btt-1-433]; [@b169-btt-1-433]). As mentioned above, for these patients, alternative therapies have to be considered. One possibility are novel kinase inhibitors or drugs that act independent of BCR/ABL (Martinelli et al 2005; [@b67-btt-1-433]; [@b158-btt-1-433]; [@b81-btt-1-433]) ([Table 3](#t3-btt-1-433){ref-type="table"}). Another option is SCT with or without a second generation BCR/ABL inhibitor ([@b80-btt-1-433]; [@b109-btt-1-433]).

An interesting aspect is that BCR/ABL TK inhibitors, when applied in combination, may produce antileukemic effects on CML cells exhibiting BCR/ABL T315I, even if leukemic cells are resistant against single agents ([@b176-btt-1-433]; [@b170-btt-1-433]). This phenomenon may be explained by additional drug targets expressed in these cells, by cooperative effects at BCR/ABL epitopes, or by increased drug accumulation in target cells ([@b176-btt-1-433]; [@b170-btt-1-433]). Whether combinations of TK inhibitors will also induce long lasting remission in (all) patients with TK-inhibitor resistant CML, remains at present unknown. It also remains unknown which of the new drugs, that have been described to counteract in vitro growth of leukemic cells exhibiting BCR/ABL T315I ([@b161-btt-1-433]; [@b26-btt-1-433]; [@b56-btt-1-433]; [@b27-btt-1-433]; [@b133-btt-1-433]), will induce complete (and long lasting) cytogenetic remissions in vivo in these patients.

An important therapeutic consideration is prevention of occurrence (selection) of subclones carrying imatinib-resistant BCR/ABL mutants. One approach may be to combine TK inhibitors in an early phase of disease, similar to the situation in HIV-positive patients, where early intervention is performed using multiple drugs. Another strategy may be to combine novel TK inhibitors with a stem cell-attacking approach, like SCT or high-dose chemotherapy, or with stem cell-suppressing maintenance therapy (eg, interferon-alpha).

Finally, several treatment concepts focus on the mobilization of the immune system, with the ultimate goal to target residual leukemic (stem) cells (MRD) in CML ([@b97-btt-1-433]; [@b174-btt-1-433]; [@b165-btt-1-433]; [@b126-btt-1-433]). In most instances, immunotherapy is combined with a BCR/ABL TK inhibitor. Whether such intervention may lead to the eradication of (all) relevant CML stem cell subclones remains to be elucidated.

Other BCR/ABL defects
=====================

Apart from *BCR/ABL* mutations, other defects in BCR/ABL may also contribute to resistance against imatinib. Such alternative defects include *BCR/ABL* gene duplications and -amplifications ([@b95-btt-1-433]; [@b171-btt-1-433]; [@b61-btt-1-433]; [@b114-btt-1-433]; [@b25-btt-1-433]; [@b111-btt-1-433]; [@b54-btt-1-433]; [@b53-btt-1-433]). These defects may be associated with (multiple) cytogenetic abnormalities ([@b53-btt-1-433]; [@b129-btt-1-433]), and several of these patients are in an accelerated phase or blast phase of CML ([@b157-btt-1-433]; [@b53-btt-1-433]; [@b129-btt-1-433]). Therefore, in most cases, the contribution of amplified *BCR/ABL* in the malignant process (progression) and in drug resistance remains uncertain. Nevertheless, some of these patients respond to elevated doses (or even standard doses) of imatinib, suggesting that the *BCR/ABL* defect may have pharmacologic and clinical impact.

BCR/ABL-independent molecular resistance
========================================

During disease, the CML clone may acquire additional BCR/ABL-independent molecular (genetic) defects and pro-oncogenic hits in stem cell subclones, which may lead to disease-progression. Such clonal evolution is often accompanied by the occurrence of cytogenetic defects. Leukemic cells in these patients are frequently resistant against imatinib, and may exhibit aneuploidy, sometimes in form of a second Ph chromosome or trisomy 8 (+8) ([@b71-btt-1-433]). Other cytogenetic defects that have been described in imatinib-resistant CML include trisomy 6 (+6), +9, +12, +18, and monosomy 7 (−7) ([@b71-btt-1-433]; [@b32-btt-1-433]; [@b103-btt-1-433]; [@b119-btt-1-433]). Most cytogenetic defects are considered to be of prognostic significance concerning survival in imatinib-treated patients ([@b32-btt-1-433]; [@b103-btt-1-433]; [@b119-btt-1-433]). However, not all cytogenetic defects may lead to imatinib-resistance. Especially isolated chromosome defects may disappear or persist at stable (low) level without loss of hematologic response during therapy. In other patients, resistance may develop within short time.

The molecular defects that accompany cytogenetic abnormalities and may contribute to resistance against imatinib, have not been defined yet. Therefore, at present, it is difficult to predict the clinical impact of isolated cytogenetic defects for imatinib-treated patients. A special situation is the occurrence of cytogenetic defects in Ph-negative subclones during imatinib therapy ([@b106-btt-1-433]; [@b159-btt-1-433]; [@b100-btt-1-433]; [@b99-btt-1-433]; [@b112-btt-1-433]; [@b79-btt-1-433]). One hypothesis is that these subclones derive from a very immature progenitor that was involved in a pre-Ph (pre-BCR/ABL) phase of CML ([Figure 1](#f1-btt-1-433){ref-type="fig"}), and under certain circumstances can be activated (by additional hits) to transform into a secondary Ph-negative (but still monoclonal) neoplasm. Indeed, some of these patients may develop overt secondary disease (that may resemble a myelodysplastic syndrome, MDS or acute myeloid leukemia, AML), even if the Ph-positive (sub)clones are completely suppressed ([@b100-btt-1-433]; [@b99-btt-1-433]; [@b112-btt-1-433]; [@b79-btt-1-433]). The subclone hypothesis is supported by HUMARA analysis as well as the fact, that the karyotype abnormalities are the same as those detectable in Ph-positive subclones ([@b159-btt-1-433]; [@b112-btt-1-433]; [@b79-btt-1-433]). An alternative hypothesis is that Ph-negative clones develop independent of the primary disease (unrelated clone). Such hypothesis would pose the question as to whether imatinib exhibits a substantial mutagenic potential and can attack normal stem cells similar to conventional cytostatic drugs. So far, no clear evidence for such hypothesis has been presented, although single case reports have suggested that even transplanted normal stem cells may undergo transformation and accumulate cytogenetic defects during treatment with imatinib ([@b3-btt-1-433]). However, again, such additional clones may not be relevant clinically (in all patients), and these patients may still stay in a complete hematologic remission with normal blood counts over time ([@b3-btt-1-433]).

As mentioned above, little is known so far about specific molecular defects and mechanisms underlying BCR/ABL-independent resistance to imatinib in CML, and especially about defects that can lead to malignant transformation in subclones. In fact, although an extensive number of (potentially deregulated) molecules and numerous mechanisms have been discussed, no specific recurrent gene defects that would explain transformation of CML into AP or BP have been identified ([@b24-btt-1-433]; [@b107-btt-1-433]). General pathogenetic factors that have been discussed as being involved in disease progression in CML include activation of (mutation-induced) signal transduction molecules (by mutations or oncogene activation), differentiation arrest, genomic instability (deficiency of DNA repair, mutator phenotype), telomer shortening, and loss of tumor suppressor function ([@b24-btt-1-433]; [@b107-btt-1-433]). Some of these defects may be triggered in part also by BCR/ABL. Likewise, BCR/ABL has been implicated in hypermethylation of the genome, in deactivation of tumor suppressors, and in the hypermutation-status of leukemic cells ([@b113-btt-1-433]; [@b107-btt-1-433]). However, most of the secondary transforming hits in CML may be BCR/ABL-independent events. The (numerous) candidate genes potentially involved in disease progression in CML, and their function, have been reviewed elsewhere ([@b24-btt-1-433]; [@b107-btt-1-433]).

So far, it remains unknown which of these defects and deregulated molecules may contribute to resistance against imatinib in CML. Respective preclinical and clinical studies are in progress and hopefully will reveal new important therapeutic targets in the near future. Such studies focus primarily on genes involved in the differentiation block, in abnormal signalling, in abnormal DNA repair, and in the deactivation of tumor suppressors ([@b104-btt-1-433]; [@b107-btt-1-433]). It is the hope for the future that these studies will lead to the development of new treatment strategies aimed at preventing disease-progression in CML. A likely scenario is that such novel therapies will then be combined with most effective BCR/ABL TK inhibitors.

Intolerance and side effects
============================

An important aspect in the treatment of CML with imatinib or other BCR/ABL TK inhibitors, are side effects that may lead to dose-reductions and thus may predispose for the development of resistance. For imatinib, only a few major side effects have been reported, including transient edema formation and mild myelosuppression ([@b44-btt-1-433]; [@b87-btt-1-433]; [@b8-btt-1-433]; [@b156-btt-1-433]; [@b144-btt-1-433]; [@b117-btt-1-433]). Other side effects such as hepatic dysfunction or cardiac problems are uncommon. However, some of these side effects may lead to dose reductions or even to drug withdrawal. Nilotinib (AMN107) also exhibits a favorable toxicity profile, although rare adverse side effects such as an elevation in pancreatic enzymes, have been reported ([@b88-btt-1-433]). With regard to dasatinib, a number of side effects have been reported using the proposed standard dose of 2 × 70 mg per os daily. These side effects include pleural and pericardial effusions and myelosuppression ([@b155-btt-1-433]; [@b70-btt-1-433]). Based on first observations in clinical trials and unpublished data, the frequency of side effects may be lower when the dose of dasatinib is reduced, which points to the question as to whether the standard dose should be reconsidered. Notably, dasatinib is a most potent inhibitor of leukemic cell growth in CML, and in many patients, the drug may still work at reduced dose levels ([@b155-btt-1-433]; [@b69-btt-1-433]). Some of the side effects may also be less frequent when the drug is administered once daily (1 × 140 mg instead of 2 × 70 mg).

For most other TK inhibitors, side effect profiles in CML patients remain to be established.

Clinical practice: Algorithm
============================

Definitions for 'suboptimal response' and 'drug-resistance' in CML patients treated with imatinib are well established ([@b7-btt-1-433]). It is also well established, that patients with drug resistance should undergo restaging and BCR/ABL mutation analysis. In addition, the availability of a SCT donor should be (re)explored. The final treatment plan will be based on a number of different variables, including disease-specific factors (phase of disease, presence and type of *BCR/ABL* mutation, presence and type of additional chromosomal abnormalities, extramedullary involvement, lymphoid versus myeloid blasts), patient-related factors (age, fitness, comorbidity, patients attitude, availability of a donor), and the overall situation in each case. After having collected all necessary information (including BCR/ABL mutations, and if required an imatinib trough level), a straight forward approach may be to estimate chances for long term disease-free survival (cure in young patients) with each therapeutic approach, and to weigh treatment-associated mortality and morbidity against the chances for cure (long term disease-free survival). Depending on mutations and other features of the clone, some patients may benefit from imatinib dose-escalation. In other cases, treatment has to be switched to dasatinib or nilotinib. Both drugs are registered and approved for treatment of imatinib-resistant CML. The decision to introduce such therapy should be based on a thorough investigation for BCR/ABL mutations, as treatment will fail when CML cells display the T315I mutant. For these patients, alternative treatment approaches have to be considered. In younger patients with a suitable donor who display BCR/ABL T315I or other highly resistant mutants, allogeneic SCT should be considered. When no donor is available or the patient is not considered fit enough for SCT, new experimental drugs, some of them known to target BCR/ABL T315I, or drug combinations, should be offered in clinical trials.

Summary and future perspectives
===============================

Resistance against imatinib is an emerging problem in the treatment of CML. Dose-adjustments, new BCR/ABL-targeting drugs, and other antileukemic approaches may be sufficient to overcome resistance in many cases. A specific challenge remains the T315I mutant of BCR/ABL that is resistant against most available TK inhibitors. Other specific challenges are the intrinsic resistance of CML stem cells, clonal evolution, involvement of BCR/ABL-independent signalling pathways, and poor accumulation of imatinib in the central nervous system. For the future, new more effective BCR/ABL TK inhibitors, drug combinations, and drugs entering the blood--brain barrier, may be straightforward approaches to improve anti-CML therapy. Such approaches will also aim at preventing the occurrence of drug resistance in an early phase of CML. For those patients who fail drug therapy and are eligible, allogeneic stem cell transplantation with or without additional TK inhibitors, will remain an alternative option of treatment. The value of new future treatment strategies (immunotherapies, siRNA) remains at present unknown.

![Evolution of CML with prephases---a proposed hypothesis.\
**Abbreviations:** Ph, Philadelphia chromosome; CML, chronic myeloid leukemia; AML, acute myeloid leukemia.](btt-1-433f1){#f1-btt-1-433}

###### 

Resistance of CML stem cells against imatinib: Proposed hypotheses[\*](#tfn1-btt-1-433){ref-type="table-fn"}

  Observations                                      Specific hypothesis/ molecular basis
  ------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stem cell quiescence (dormance)                   G0 arrest by chalones or by specific cell cycle regulators, quite similar mechanisms may lead to dormance of normal stem cells[\*\*](#tfn2-btt-1-433){ref-type="table-fn"}
  Stem cell plasticity                              Development of subclones may be facilitated by mechanisms similar to those responsible for differentiation of normal myeloid stem cells into various myeloid lineages[\*\*](#tfn2-btt-1-433){ref-type="table-fn"} -- exact mechanisms are unknown
  Overexpression of BCR/ABL                         BCR/ABL mRNA and protein over- expression -- mechanisms unknown
  Specific BCR/ABL-induced stem cell deregulation   Altered DNA repair; hypermethylation; induction of stem cell subclones. Over time, BCR/ABL may overcome some of the stem cell-protecting mechanisms
  BCR/ABL-independent survival                      Stem cell-specific survival factors; altered survival factors in subclones[\*\*\*](#tfn3-btt-1-433){ref-type="table-fn"}
  Decreased uptake of imatinib                      Decreased expression of OCT-1, a major transporter of imatinib
  Increased drug efflux                             Overexpression of P-glycoprotein(MDR-1) and other efflux pumps[\*\*\*\*](#tfn4-btt-1-433){ref-type="table-fn"}

**Notes:**

Relate all to differences between CML stem cells and more mature CML cells. The following articles refer to these concepts: [@b30-btt-1-433], [@b29-btt-1-433]; [@b9-btt-1-433]; [@b21-btt-1-433]; [@b84-btt-1-433]);

The biology of normal stem cells and CML stem cells may be quite similar;

CML stem cells may even survive after complete deactivation of BCR/ABL;

Normal and neoplastic stem cells may defend their long-term existence against external 'enemies' (toxins, drugs) by high toxin/drug efflux.

**Abbreviations:** OCT-1, organic cation transporter; MDR-1, multidrug resistance gene-1.

###### 

BCR/ABL mutations detectable in CML patients treated with imatinib

  Mutant    IC50[\*](#tfn6-btt-1-433){ref-type="table-fn"} imatinib   may benefit from IM-dose-escalation[\*\*](#tfn7-btt-1-433){ref-type="table-fn"}   IC50[\*](#tfn6-btt-1-433){ref-type="table-fn"} dasatinib   IC50[\*](#tfn6-btt-1-433){ref-type="table-fn"} nilotinib
  --------- --------------------------------------------------------- --------------------------------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------
  no (wt)   250--500                                                  \-                                                                                0.8                                                        13
  M244V     1,600--3,100                                              yes                                                                               1.3                                                        38
  M244I     1,400                                                     yes                                                                               nk                                                         nk
  G250E     \>1,000 (\>3,000)                                         no                                                                                1.8                                                        48
  Q252H     1,300--2,900                                              yes                                                                               3.4                                                        70
  Y253H     4,000--17,000                                             no                                                                                1.3                                                        450
  Y253F     1,800--5,000                                              no                                                                                1.4                                                        125
  E255K     5,000--12,000                                             no                                                                                5.6                                                        200
  E255V     6,000--20,000                                             no                                                                                11                                                         430
  F311L     480--1,300                                                no                                                                                1.3                                                        23
  T315I     \>10,000                                                  no                                                                                \>200                                                      \>2,000
  F317L     1,000--2,300                                              no                                                                                7.4                                                        50
  M351T     900--4,900                                                yes                                                                               1.1                                                        15
  M351I     1,600                                                     yes                                                                               nk                                                         nk
  F359V     1,400--1,800                                              yes                                                                               2.2                                                        175
  E355G     2,000--2,400                                              yes                                                                               nk                                                         nk
  V379I     1,000--1,600                                              yes                                                                               0.8                                                        51
  L387M     1,000--1,100                                              yes                                                                               2                                                          49
  H396P     850--4,300                                                no                                                                                0.6                                                        41
  H396R     1,750--5,400                                              no                                                                                1.3                                                        41

**Notes:**

IC50 values are given in nM and refer to published data obtained with Ba/F3 cells exhibiting wild type BCR/ABL or various BCR/ABL mutants using cell -- proliferation assays ([@b120-btt-1-433]; [@b104-btt-1-433]);

recommendations are derived from [@b104-btt-1-433]).

**Abbreviations:** IM, imatinib; wt, wild type; nk, not known.

###### 

Novel pharmacologic inhibitors proposed for imatinib-resistant CML

  Drug name                       Drug type class          Known target(s)                      active in cells bearing BCR/ABL T315I
  ------------------------------- ------------------------ ------------------------------------ -----------------------------------------------
  Dasatinib (Sprycel)             TKI                      Abl, Src, Lyn, Btk, Kit, PDGFR,      no
  Nilotinib (Dasigna)             TKI                      Abl, Kit, PDGFR, \...\...            no
  SKI-606 (Bosutinib)             TKI                      Abl, Src, ..                         no
  INNO-406 (NS-187)               TKI                      Abl, Lyn, Kit, ..                    no
  AZD0530                         TKI                      Abl, Src, ..                         no
  AP23464                         TKI                      Abl, Src, ..                         no
  CGP76030                        TKI                      Abl, Src, ..                         +/−[\*](#tfn9-btt-1-433){ref-type="table-fn"}
  PP1                             TKI                      Abk, Src, ..                         +/−[\*](#tfn9-btt-1-433){ref-type="table-fn"}
  PD166326                        TKI                      Abl, Src, ..                         no
  ON012380                        TKI                      Abl, PDGFR, Lyn                      yes
  MK-0457 (VX-680), other AuK-I   AuK-I                    Aurora-kinase                        yes
  BIRB-796, 43-9006 (sorafenib)   p38-I                    p38 MAP kinase, (Abl)                no
                                  Kinase-I                 multiple kinases, Mcl-1              yes
  WP1130                          \-                       ? (Jak, Abl-knock-down)              yes
  various                         hypomethylating agents   re-expression of tumor suppressors   +/−
  various                         Hsp-I                    Hsp32, Hsp70, Hsp90, ...             yes
  various compounds               FTIs                     RAS                                  +/−
  various compounds               PI3K-I                   PI3-kinase                           yes
  Rapamycin and its derivatives   mTOR-I                   mTOR                                 yes

**Notes:**

relatively high drug concentrations needed to block growth of cells.

**Abbreviations:** TKI, tyrosine kinase inhibitor; PDGFR, platelet derived growth factor receptor; Hsp, heat shock proteins; FTI, farnesyl transferase inhibitor; mTOR, mammalian target of rapamycin.
